OrigiMed

About OrigiMed

OrigiMed, established in Shanghai in May 2016 by co-founders Dr. Kai Wang, Hui Kang, and Catherine Qin, operates as a data-driven precision medicine company focused on oncology. The firm is dedicated to providing comprehensive molecular diagnostic information to cancer patients and offers genomics services to biopharmaceutical partners to support the development of biomarker-driven drugs.

The company's business model is centered on leveraging high-throughput, next-generation sequencing (NGS) technologies to analyze the genomic features of tumors. This allows for the identification of specific molecular markers that can guide targeted therapies and immunotherapies for cancer patients. OrigiMed serves a diverse client base that includes individual patients, over 200 teaching hospitals and a thousand doctors across China, as well as pharmaceutical and insurance companies. For biopharma partners, the company provides solutions to accelerate drug development, from identifying novel biomarkers to supporting clinical trials with real-world data. Revenue is generated through these diagnostic services, partnerships with pharmaceutical companies, and collaborations with insurance firms to create tailored products.

A core offering is the company's comprehensive genomic profiling, which analyzes a wide range of solid tumor types. Its laboratories are CLIA certified and CAP accredited. OrigiMed has developed proprietary bioinformatics algorithms and maintains one of China's largest pan-cancer real-world databases, OMSmartData, which integrates clinical, pathological, and genomic data to support oncology drug development. This platform helps pharmaceutical clients to define patient populations, visualize data, and accelerate insights, reportedly saving significant time and cost in data collection for studies. The company has also launched several cutting-edge NGS products for purposes like minimal residual disease (MRD) monitoring, and a mobile platform called "Dr. Groundhog" for sharing precision medicine data.

Since its inception, OrigiMed has achieved significant milestones, including multiple rounds of financing from investors like IDG Capital, Grand Flight Investment, and Star Ventures. The company has established a prestigious Scientific Advisory Board with internationally recognized experts in cancer genomics and immunotherapy. A pivotal achievement was a large-scale study on the genomic characteristics of Asian cancer populations, which filled a significant data gap and found that 64% of Chinese cancer patients have a clinically druggable gene mutation. This provides a crucial evidence base for advancing precision medicine in China. OrigiMed has also formed strategic partnerships with entities like the CSCO Foundation, Ping An Health Insurance, and pharmaceutical companies such as Janssen and Bayer to build an innovative ecosystem for precision medicine.